Introduction {#section5-2049936118811053}
============

Nowadays, we are experiencing a worldwide proliferation of extended-spectrum beta-lactamase (ESBL) strains which is a major public health threat, according to the Centers for Disease Control and Prevention (CDC).^[@bibr1-2049936118811053]^ Carbapenems are deemed to be the standard regimen, but alternatives are currently evaluated considering the emergence of resistance to carbapenems with the risk of deadlock situation.

Cefoxitin (FOX), a cephamycin, was rapidly replaced by third-generation cephalosporins in the 1980s because of a better efficacy against gram-negative bacteria.^[@bibr2-2049936118811053]^ Nevertheless, FOX has a good *in vitro* activity and stability because of a grouping 7-α-methoxy that inhibits the action of ESBLs by its shape.^[@bibr3-2049936118811053]^

Therefore, FOX has been repurposed to treat ESBL infections, especially after the study of Lepeule and colleagues^[@bibr4-2049936118811053]^ in 2012 that highlighted its comparable activity to carbapenems against CTX-M-15-producing *Escherichia coli* strains, with similar bactericidal activities and selective pressure.

On the other hand, the use of FOX in *Klebsiella pneumoniae* infections has been controversial since 1989 due to a case report describing a porin-deficient mutant of a TEM-3 beta-lactamase (Omp K35) after a cephamycin exposure.^[@bibr5-2049936118811053]^ Recently, Ananthan and colleagues^[@bibr6-2049936118811053]^ showed that such resistance (mediated by Omp K35) could be observed also for ESBL *E. coli*.

The aim of this study was to evaluate FOX in ESBL urinary tract infections (UTIs) and whether the type of microorganism impacts the outcome.

Methods {#section6-2049936118811053}
=======

Setting and design {#section7-2049936118811053}
------------------

We conducted a retrospective study from September 2014 to November 2017 in Raymond-Poincaré Teaching Hospital with 255 beds of acute care, located in Garches (France). The hospital is a center of expertise in neurological impairment, including spinal cord--injured patients. They are subject to bladder dysfunction with UTI and are frequently colonized by multidrug-resistant (MDR) organisms with an incidence that can reach up to twice the expected value. In 2013, ESBL-producing *Enterobacteriaceae* colonization revealed an incidence of 1.1 per 1000 patient-days, compared with 0.55 in other healthcare facilities.^[@bibr7-2049936118811053]^

FOX was chosen because of its low price (€35 for a 7-day treatment with 1 g/6 h) and considering there was no other possible alternative outside of carbapenems, especially fluoroquinolone or trimethoprim-sulfamethoxazole.

Patients were adults treated by intermittent intravenous infusion of FOX for a UTI caused by an ESBL isolate with an administration of FOX ⩾ 50% of the total duration of antibiotics. Those data were extracted by a hospital pharmacist and thereafter data were analyzed by two independent infectious disease specialists according to cytobacteriological examination of the urine (CBEU) and medical charts. Finally, to carry out analyses, the cohort was divided into two arms depending on the microorganism (*E. coli* or *K. pneumoniae*).

Microbiological definitions {#section8-2049936118811053}
---------------------------

Isolates for which the minimal inhibitory concentration (MIC) of cefotaxime decreased by three serial twofold dilutions when tested in the presence of clavulanate or for which zone diameters increased by 5 mm in the presence of clavulanate were considered positive for ESBL, as described previously.^[@bibr8-2049936118811053]^

Definition and endpoints {#section9-2049936118811053}
------------------------

The clinical information gathered included age, sex, underlying diseases to calculate a Charlson comorbidity score,^[@bibr9-2049936118811053]^ urinary system pathology, bacteremia, posology, and the duration of antibiotic regimen (including FOX and eventually oral relay).

Definitions of orchitis, pyelonephritis, and prostatitis were based on the French guidelines for the treatment of UTI.^[@bibr10-2049936118811053]^

UTI was defined by a positive urinalysis (CFU ⩾ 10^5^/mL) and at least one clinical sign: dysuria, frequency, urgency, suprapubic or costovertebral tenderness, and clinical autonomic dysreflexia (which is associated with throbbing headaches, profuse sweating, nasal stuffiness, flushing of the skin above the level of the lesion, and slow heart rate). In the absence of fever, with persistent symptoms of more than 72 h, patient was considered as suffering from cystitis.

Clinical cure was defined as resolution of symptoms without recurrence during the follow-up.

Clinical failure was defined by the persistence of symptoms during treatment or by the recurrence of symptoms within 90 days after the end of treatment. In such condition, failure was assessed by a positive urine culture during the follow-up to rule out a possible emergence of a FOX-resistant strain.

Clinical outcomes were assessed at the end of treatment and for 90 days after discontinuation of antibiotics. A follow-up CBEU was not systematically performed.

Statistical analysis {#section10-2049936118811053}
--------------------

Results are expressed as *n* (%) or median (minimum--maximum) and outcomes were assessed using Fisher's exact test. Statistical analyses were carried out using Prism v.7.0d (GraphPad Software Inc., La Jolla, CA).

Results {#section11-2049936118811053}
=======

Overall 31 patients had an ESBL UTI and were analyzed. Mean age was 60 ± 18 years. The flowchart is detailed in [Figure 1](#fig1-2049936118811053){ref-type="fig"}. Patients' characteristics are summarized in [Table 1](#table1-2049936118811053){ref-type="table"}. No patient presented with sepsis according to the latest guidelines.

![Flowchart of the studied population before inclusion in the study. All patients presented with UTI due to an ESBL isolate.\
ESBL, extended-spectrum beta-lactamase; UTI, urinary tract infection.](10.1177_2049936118811053-fig1){#fig1-2049936118811053}

###### 

Patients' characteristics -- comparison between *E. coli*- and *K. pneumoniae*-infected patients.

![](10.1177_2049936118811053-table1)

                                                                                 ESBL *E. coli* (*n* = 17)   ESBL *K. pneumoniae* (*n* = 14)   *p* value
  ------------------------------------------------------------------------------ --------------------------- --------------------------------- -----------
  *Patients*                                                                                                                                   
  Sex (male), *n* (%)                                                            12 (70.6)                   11 (78.6)                         0.69
  Age, mean (±SD) (in years)                                                     62 ± 17.9                   57 ± 18.1                         0.41
  Underlying condition, *n* (%)                                                                                                                0.99
   Neurological disorder[\*](#table-fn2-2049936118811053){ref-type="table-fn"}   7                           8                                 --
   Immunocompromised^[\$](#table-fn3-2049936118811053){ref-type="table-fn"}^     2                           2                                 --
   Urological disease^[‡](#table-fn4-2049936118811053){ref-type="table-fn"}^     5                           6                                 --
   Diabetes                                                                      2                           1                                 --
   Chronic kidney failure                                                        2                           1                                 --
  Median creatinine plasma level                                                 112 (78--143)               107 (68--121)                     0.99
  Home resident/LTCF, *n* (%)                                                    13 (76.5)/4                 10 (71.4)/4                       0.99
  Median Charlson comorbidity index (min--max)                                   4 (0--10)                   4.5 (1--9)                        0.29
  Median length of stay (min--max)                                               8 (4--31)                   10 (5--60)                        0.27
  *Infection characteristics*                                                                                                                  
  Site of infection, *n* (%)                                                                                                                   
   Pyelonephritis                                                                11 (64.7)                   11 (78.7)                         0.45
   Prostatitis                                                                   4 (23.5)                    1 (7.1)                           0.34
   Orchitis                                                                      2 (11.8)                    1 (7.1)                           0.99
   Cystitis                                                                      --                          1 (7.1)                           0.45
  Abscesses^[§](#table-fn5-2049936118811053){ref-type="table-fn"}^, *n* (%)      1 (5.9)                     1 (7.1)                           0.99
  Concomitant bacteremia, *n* (%)                                                3 (17.7)                    2 (14.2)                          0.99
  *Antibiotic regimen*                                                                                                                         
  Median duration of Cefoxitin therapy (min--max)                                10 (5--21)                  10 (5--21)                        0.41
   Pyelonephritis                                                                10 (5--21)                  10 (7--21)                        
   Prostatitis                                                                   19.5 (16--21)               21                                
   Orchitis                                                                      15.5 (10--21)               14                                
   Cystitis                                                                      --                          6                                 
  Median daily dose (min--max)                                                   4 (2--8)                    6 (3--6)                          0.53

ESBL, extended-spectrum beta-lactamase; SD, standard deviation; LTCF, long-term care facility.

Including severe cranial trauma, spine cord injury, multiple sclerosis, paraplegia/tetraplegia, and stroke under intermittent bladder catheterization (*n* = 4 in each arm).

HIV, multiple myeloma, hematological malignancy including lymphoma and cancer.

Urinary tract abnormality including urological cancer and recurrent urinary tract infection.

Abscesses were perinephric abscess or prostatic abscess of medical treatment.

Prior to the administration of FOX, 12.9% (*n* = 4) received another effective antimicrobial therapy (imipenem/cilastine) within the 48 h (for three *E. coli* isolates). Of note, three cases received an inactive therapy with a third-generation cephalosporin.

Median daily dose of FOX was 4 g (2--8). Only one patient infected by ESBL *E. coli* received an additional oral relay with 4 days of levofloxacin.

During the follow-up no patient reported any adverse event.

One patient who had a favorable outcome at day 30 died at day 40 of a cancer in palliative care and was lost to follow-up at day 90.

Overall, we noted an efficacy of FOX of 96.7% (*n* = 30/31) at day 30 and 83.3% (*n* = 25/30) at day 90. Statistical analysis revealed no particular risk factor for failure (*n* = 5), including in the case of ESBL *K. pneumoniae*-related infection ([Table 2](#table2-2049936118811053){ref-type="table"}).

###### 

Characteristics of patients who failed to cefoxitin regimen at day 90.

![](10.1177_2049936118811053-table2)

                                                    Success (*n* = 25)   Failure (*n* = 5)   *p* value
  ------------------------------------------------- -------------------- ------------------- -----------
  *Patients*                                                                                 
  Age, mean (±SD) (in years)                        58 ± 18.8            62 ± 13.9           0.41
  Charlson comorbidity index median (min--max)      4 (0--10)            4 (0--9)            0.45
  *Infection characteristics*                                                                
  Site of infection, *n*                                                                     
   Pyelonephritis                                   18                   3                   0.59
   Prostatitis                                      4                    1                   0.99
   Orchitis                                         2                    1                   0.43
   Cystitis                                         1                    --                  0.99
  Abscess, *n*                                      1                    1                   0.31
  Concomitant bacteremia, *n*                       5                    0                   0.56
  Due to a *K. pneumoniae* isolate                  12                   1                   0.35
  *Antibiotic regimen*                                                                       
  Median duration of Cefoxitin therapy (min--max)   10 (5--21)           10 (5--21)          0.41
  Median daily dose (min--max)                      4 (2--8)             6 (3--6)            0.16

SD: standard deviation.

Outcomes at day 90 were similar between the *E. coli* and *K. pneumoniae* groups with a favorable outcome in 13/16 (81.2%) and 12/14 (85.7%), respectively (*p* = 0.72; [Figure 2](#fig2-2049936118811053){ref-type="fig"}).

![Outcomes after cefoxitin therapy, considering one lost to follow-up at day 40 for the treatment of a *K. pneumoniae* UTI.\
UTI: urinary tract infection.](10.1177_2049936118811053-fig2){#fig2-2049936118811053}

Finally, 11 cases (4 *E. coli* and 7 *K. pneumoniae* isolates) benefited from microbiological follow-up. We observed only one failure in a patient suffering from prostatitis due to a *K. pneumoniae* isolate which has become intermediate to FOX later on and was retreated.

Discussion {#section12-2049936118811053}
==========

Our study showed a remarkable clinical cure (83.3% at day 90) for ESBL UTI treated by FOX. It brings new relevant data considering that our cohort is exclusively composed of UTI unlike Kerneis and colleagues^[@bibr11-2049936118811053]^ (*n* = 23), concerns both sexes unlike Demonchy and colleagues^[@bibr12-2049936118811053]^ (*n* = 23), and is mainly composed of pyelonephritis unlike Mambie and colleagues^[@bibr13-2049936118811053]^ (*n* = 15). Our results are consistent with their findings with a clinical cure in 83% at day 90,^[@bibr12-2049936118811053]^ whereas Kerneis and colleagues^[@bibr11-2049936118811053]^ reported a favorable outcome also in 83% of cases but with a different endpoint (after a median follow-up of 14 days).

Moreover, Kim and colleagues^[@bibr14-2049936118811053]^ reported a favorable outcome of 93.2% (*n* = 83/89) at day 90 using carbapenems for ESBL UTIs, thereby being not different from our series.

To our knowledge, this is the biggest cohort of UTI reported. Moreover, some of these cited studies share heterogeneous clinical and microbiological populations^[@bibr11-2049936118811053],[@bibr13-2049936118811053],[@bibr15-2049936118811053]^ that may constitute a selective bias.

Interestingly, in our study, failure was not associated with lower dosing of FOX ([Table 2](#table2-2049936118811053){ref-type="table"}). Yet, the median dose was relatively low (4 g). Although our study does not provide any arguments for lower efficacy on *K. pneumoniae* infections (*p* = 0.35), we observed the appearance of one isolate that became intermediate to FOX after a 6 g regimen of FOX for prostatitis in a patient weighting 95 kg. Therefore, physician should be worried that an Omp K35 mutation remains possible, maybe in a higher proportion for *K. pneumoniae* than *E. coli* isolates^[@bibr6-2049936118811053]^ despite the fact two different case series^[@bibr12-2049936118811053],[@bibr13-2049936118811053]^ reported no emergence of resistance with *K. pneumoniae* isolates in UTI. To answer this question, a plasma and tissue pharmacokinetics of FOX would be helpful. Indeed, Guet-Revillet and colleagues^[@bibr16-2049936118811053]^ suggested that only high dosage (8 g per day) and continuous perfusion will able to reach pharmacological targets. Nevertheless, there is no MIC breakpoint issued by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for the treatment of ESBL isolates with FOX, and only zone diameters are acknowledged.^[@bibr17-2049936118811053]^ Another limit is the absence of a systematic control urinalysis to evaluate a potential acquisition of resistance, but it is not recommended by guidelines.

In a period of major threat obliging to a policy of carbapenem-sparing regimens, it seems detrimental to deprive physicians of using FOX while our data show its efficacy. Furthermore, limiting the prescription of FOX only to *E. coli* isolates could wrongly encourage the use of carbapenems.

Further studies with larger sample size are necessary in order to confirm our findings, particularly in patients infected by ESBL *K. pneumoniae* isolates.
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